Navigation Links
Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
Date:7/17/2009

SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of the three remaining Phase 3 clinical trials in the Contrave program on Monday, July 20, 2009 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time.

Orexigen management will host the call and webcast to discuss the results of these clinical trials and answer questions. The live call may be accessed by phone by calling 1-800-561-2813 (domestic) or 617-614-3529 (international), participant code 14007929. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM) which is in the later stages of Phase II development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County ... its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The ... disinfection robot that uses UVC light energy to kill deadly pathogens such as C. ... Tru-D SmartUVC ... Tru-D in action in ...
(Date:8/2/2017)... a next-generation full-service pharmacy, has announced the launch of its ... Washington D.C. metropolitan area. CaryRx aims to ... through the convenience of its patient-friendly mobile app. Prescriptions can ... to any location in D.C. ... Washington D.C. ," says Areo Nazari , ...
(Date:7/31/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named one ... by Crain,s Detroit Business . The annual ... three-year revenue growth. This year,s edition measures growth from 2013 ... the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... said Phil Hagerman , CEO and chairman of Diplomat. ...
Breaking Medicine Technology:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... with events taking place all over the country. , Outdoor running increases exposure ... runners are at an increased risk of melanoma, and only half may be ...
(Date:8/21/2017)... CA (PRWEB) , ... August 21, 2017 , ... The ... how exactly are we supposed to get things done in a healthy way these ... And, they’re launching a crowdfunding campaign on August 28 to introduce Deskcise Pro™– the ...
(Date:8/21/2017)... ... ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse Executive ... of Trustees for a three-year term beginning January 1, 2018. , The ... are committed to the improvement of health in their communities. Founded in 1898, the ...
(Date:8/21/2017)... CA (PRWEB) , ... August 21, 2017 , ... ... health services business of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar ... responders affected by post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over ...
(Date:8/20/2017)... ... August 20, 2017 , ... A total solar eclipse will occur across the ... as the moon moves between the sun and Earth. This rare event will be magnificent ... can help keep you safe on the road during the total eclipse of the sun. ...
Breaking Medicine News(10 mins):